Respuesta a la terapia inmunosupresora de rescate con rituximab en pacientes con nefritis lúpica en la región Caribe Colombiana
| datacite.rights | http://purl.org/coar/access_right/c_16ec | |
| dc.contributor.advisor | Aroca Martínez, Gustavo José | |
| dc.contributor.advisor | Castillo Parodi, Luis | |
| dc.contributor.author | Mercado Del Vecchio, Giovanni Fabricio | |
| dc.date.accessioned | 2022-02-09T13:53:22Z | |
| dc.date.available | 2022-02-09T13:53:22Z | |
| dc.date.issued | 2022 | |
| dc.description.abstract | Antecedentes: El Lupus Eritematoso Sistémico (LES), afecta prácticamente a todos los aparatos y sistemas del cuerpo humano; sin embargo, las manifestaciones cutáneas son las más comunes (90%) y la afección renal (NL) le confiere un pronóstico especial. En este sentido la NL es una complicación frecuente en esta enfermedad, con una importante influencia en el pronóstico de la misma aumentando la morbimortalidad de los pacientes que la padecen. Objetivo: Describir la respuesta a la terapia inmunosupresora de rescate con Rituximab en pacientes con nefritis lúpica en la Región Caribe Colombiana. Metodología: Se presenta un tipo de estudio retrospectivo con una profundidad descriptiva y una finalidad aplicada con un carácter de medida cuantitativo esta investigación fue la ciudad de Barranquilla (ATL, CO). La población estuvo constituida por los pacientes registrados en Clinical Report File (CRF) de la Clínica donde se realizó la investigación, durante el periodo 2020 y 2021. Se diseñaron tablas y gráficos descriptivos para cada una de las variables, se efecto comparaciones aquellas que fueran pertinente a través de un Test de χ². Los datos fueron registrados en Excel y analizado con Statgraphic®. Resultados: Se evaluaron un total de 18 pacientes que no respondieron a la terapia estándar de inducción con MCF o/y CFZ. En cuanto a la representación por genero las mujeres fueron mayoría. La edad mínima registrada fue de 22 años y la máxima de 53 años, la de los hombres fue mínima de 41 a una máxima de 43 años. Al comparar las edades entre los sexos, no se encontró una diferencia estadísticamente significativa con una confianza del 95% (W: 8.0; p-valor: 0,4434). De los pacientes que no tuvieron respuesta, el esquema que presento mayor tasa de no respuesta fue el de CFZ con un 67%, mientras que el MFC tuvo una tasa de 67. En cuanto, a la tasa de repuesta, el 47% No tuvieron una respuesta clínica el 47% pacientes, una respuesta parcial el 33% y solo el 20% una respuesta completa. Conclusión: La respuesta a la terapia de rescate es independiente al sexo, así como la tasa de respuesta completa con terapia de rescate con Rituximab es baja y que aquellos pacientes que respondieron a la terapia de rescate recuperaron medianamente su TFG, por lo tanto, hay que seguir haciendo controles más cercanos para establecer mejor su. | spa |
| dc.description.abstract | Background: Systemic Lupus Erythematosus (SLE), affects practically all the apparatus and systems of the human body; however, skin manifestations are the most common (90%) and kidney disease (LN) confers a special prognosis. In this sense, LN is a frequent complication in this disease, with an important influence on its prognosis, increasing the morbidity and mortality of patients who suffer from it. Objective: To describe the response to rescue immunosuppressive therapy with Rituximab in patients with lupus nephritis in the Colombian Caribbean Region. Methodology: A type of retrospective study is presented with a descriptive depth and an applied purpose with a quantitative measurement character. This research was the city of Barranquilla (ATL, CO). The population consisted of the patients registered in the Clinical Report File (CRF) of the Clinic where the investigation was carried out, during the period 2020 and 2021. Descriptive tables and graphs were designed for each of the variables, comparisons were made for those that were relevant through a χ² Test. The data was recorded in Excel and analyzed with Statgraphic®. Results: A total of 18 patients who did not respond to standard induction therapy with MCF and/or CFZ were evaluated. Regarding representation by gender, women were the majority. The minimum age recorded was 22 years and the maximum was 53 years; that of men was a minimum of 41 to a maximum of 43 years. When comparing the ages between the sexes, no statistically significant difference was found with 95% confidence (W: 8.0; p-value: 0.4434). Of the patients who did not have a response, the regimen that presented the highest rate of non-response was the CFZ with 67%, while the MFC had a rate of 67. As for the response rate, 47% did not have a clinical response 47% patients, a partial response 33% and only 20% a complete response. Conclusion: The response to rescue therapy is independent of gender, as well as the rate of complete response with rescue therapy with Rituximab is low and that those patients who responded to rescue therapy moderately recovered their GFR, therefore, it is necessary to continue making closer checks to better establish your | eng |
| dc.format.mimetype | ||
| dc.identifier.uri | https://hdl.handle.net/20.500.12442/9356 | |
| dc.language.iso | spa | |
| dc.publisher | Ediciones Universidad Simón Bolivar | spa |
| dc.publisher | Facultad de Ciencias de la Salud | spa |
| dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | eng |
| dc.rights.accessrights | info:eu-repo/semantics/restrictedAccess | eng |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | |
| dc.subject | Rituximab | spa |
| dc.subject | Respuesta al tratamiento | spa |
| dc.subject | Nefritis lúpica | spa |
| dc.subject | Rituximab | eng |
| dc.subject | Response to treatment | eng |
| dc.subject | Lupus nephritis | eng |
| dc.title | Respuesta a la terapia inmunosupresora de rescate con rituximab en pacientes con nefritis lúpica en la región Caribe Colombiana | spa |
| dc.type.driver | info:eu-repo/semantics/other | |
| dc.type.spa | Otros | |
| dcterms.references | de Zubiria Salgado A, Herrera-Diaz C. Lupus nephritis: an overview of recent findings. Autoimmune Dis [Internet]. 2012 Jan [cited 2014 Nov 6];2012:849684. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3318208&tool=pmcentrez&rendertype=abstract | eng |
| dcterms.references | Font J, Cervera R. ¿Qué hacer para mejorar la supervivencia de los pacientes con lupus eritematoso sistémico? Med Clin (Barc). 2007;128(3):95–6. | spa |
| dcterms.references | Nangaku M, Shankland SJ, Couser WG. Cellular response to injury in membranous nephropathy. J Am Soc Nephrol [Internet]. 2005 May [cited 2014 Dec 11];16(5):1195–204. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15800119 | eng |
| dcterms.references | Egido De Los Ríos J, Ortiz Arduán A. Nefropatías glomerulares. In: Hernando Avendaño L, Aljama García P, Arias Rodríguez M, Caramelo Díaz C(†), Egido De Los Ríos J, Peláez Lamas S, editors. Nefrología Clínica. 4ta ed. Madrid, España: Editorial Panamericana; 2003. p. 302–8. | spa |
| dcterms.references | Naranjo LAG, Duque GMV, Uribe OU, Gómez LAR. Nefropatía lúpica. Presentación clínica, clasificación y tratamiento. Rev Colomb Reumatol. 2006;13(4):307–33. | spa |
| dcterms.references | Navarra S V., Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet [Internet]. 2011 Feb;377(9767):721–31. Available from: http://dx.doi.org/10.1016/S0140-6736(10)61354-2 | eng |
| dcterms.references | Navarra S V., Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9767):721–31. | eng |
| dcterms.references | Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012;64(4):1215–26. | eng |
| dcterms.references | Ward MM, Pajevic S, Dreyfuss J, Malley JD. Short-term prediction of Ward MM, Pajevic S, Dreyfuss J, Malley JD. Short-term prediction of mortality in patients with systemic lupus erythematosus: classification of outcomes using random forests. Arthritis Rheum [Internet]. 2006 Feb 15;55(1):74–80. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16463416 | eng |
| dcterms.references | Contreras G, Lenz O, Pardo V, Borja E, Cely C, Iqbal K, et al. Outcomes in African Americans and Hispanics with lupus nephritis. Kidney Int [Internet]. 2006 May;69(10):1846–51. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16598205 | eng |
| dcterms.references | Yap DYH, Tang CSO, Ma MKM, Lam MF, Chan TM. Survival analysis and causes of mortality in patients with lupus nephritis. Nephrol Dial Transplant [Internet]. 2012 Aug 1;27(8):3248–54. Available from: https://academic.oup.com/ndt/article-lookup/doi/10.1093/ndt/gfs073 | eng |
| dcterms.references | Mohan C, Putterman C. Genetics and pathogenesis of systemic lupus erythematosus and lupus nephritis. Nat Rev Nephrol [Internet]. 2015;11(6):329–41. Available from: http://www.nature.com/doifinder/10.1038/nrneph.2015.33 | eng |
| dcterms.references | Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) [Internet]. 2012 Jun;64(6):797–808. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22556106 | eng |
| dcterms.references | Arnaud L, Fagot J-P, Mathian A, Paita M, Fagot-Campagna A, Amoura Z. Prevalence and incidence of systemic lupus erythematosus in France: A 2010 nation-wide population-based study. Autoimmun Rev. 2014 Nov;13(11):1082–9. | eng |
| dcterms.references | Koutsokeras T, Healy T. Systemic lupus erythematosus and lupus nephritis. 2014; | eng |
| dcterms.references | Gurevitz SL, Snyder JA, Wessel EK, Frey J, Williamson BA. Systemic lupus erythematosus: A review of the disease and treatment options. Consult Pharm. 2013;28(2):110–21. | eng |
| dcterms.references | Viana De Queiroz M. Lupus Eritematoso Sistemico. Acta Med Port. 1994;7(6):343–8. | spa |
| dcterms.references | pe Corona-Sanchez EG. Lupus eritematoso sistémico: implicaciones de la inmunidad innata. El Resid. 2015;10(1):4–11. | spa |
| dcterms.references | Cervera R, Khamashta M a, Font J, Sebastiani GD, Gil A, Lavilla P, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore). 2003;82(5):299–308. | spa |
| dcterms.references | Gul H, Mushtaq MS, Salim B, Samreen S, Nasim A, Khan M. A Comparison Of Mycophenolate Mofetil And Cyclophosphamide As Lupus Nephritis Induction Therapy. J Ayub Med Coll Abbottabad [Internet]. 2020;32(4):454–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/33225643 | eng |
| dcterms.references | Rathi M, Goyal A, Jaryal A, Sharma A, Gupta PK, Ramachandran R, et al. Comparison of low-dose intravenous cyclophosphamide with oral mycophenolate mofetil in the treatment of lupus nephritis. Kidney Int [Internet]. 2016 Jan;89(1):235–42. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26489028 | eng |
| dcterms.references | Fava A, Petri M. Systemic lupus erythematosus : Diagnosis and clinical management. J Autoimmun. 2019;96(September 2018):1–13. | eng |
| dcterms.references | Acosta I, Avila G, Acosta M, Aquino A, Centurión O. Manifestaciones clínicas y laboratoriales en el Lupus eritematoso sistemico- LES. 2016;14(1). | spa |
| dcterms.references | Alonso M. Lupus eritematoso sistémico. Epidemiología y presentación clínica en el noroeste de España. UNIVERSIDAD DE CANTABRIA; 2017. | spa |
| dcterms.references | Ceccarelli F, Perricone C, Cipriano E, Massaro L, Natalucci F, Capalbo G, et al. Joint involvement in systemic lupus erythematosus: From pathogenesis to clinical assessment. Semin Arthritis Rheum. 2017 Aug;47(1):53–64. | eng |
| dcterms.references | Kolasinski SL, Chi AS, Lopez-Garib AJ. Current Perspectives on Imaging for Systemic Lupus Erythematosus, Systemic Sclerosis, and Dermatomyositis/Polymyositis. Rheum Dis Clin North Am. 2016 Nov;42(4):711–32. | eng |
| dcterms.references | Azoicăi T, Belibou IM, Lozneanu L, Giuşcă SE, Cojocaru E, Căruntu ID. Large variability of the activity and chronicity indexes within and between histological classes of lupus nephritis. Rom J Morphol Embryol [Internet]. 2017;58(1):73–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28523301 | eng |
| dcterms.references | Koo BS, Hong S, Kim YJ, Kim Y-G, Lee C-K, Yoo B. Lupus enteritis: clinical characteristics and predictive factors for recurrence. Lupus. 2015 May;24(6):628–32. | eng |
| dcterms.references | Brewer BN, Kamen DL. Gastrointestinal and Hepatic Disease in Systemic Lupus Erythematosus. Rheum Dis Clin North Am. 2018 Feb;44(1):165–75. | eng |
| dcterms.references | Mart GA, Gonz HJ. Nefritis lúpica. (11). | spa |
| dcterms.references | Novillo Valdivieso MS, Ayala López IM, Mora Gonzalez MG, Hurtado Herdoiza LO. Diagnóstico y tratamiento de la nefritis lúpica. Recimundo. 2019;3(3):410–27. | spa |
| dcterms.references | Horta-Baas G, Camargo-Coronel A, Miranda-Hernández DG, Gónzalez-Parra LG, Romero-Figueroa M del S, Pérez-Cristóbal M. Renal Transplantation in Systemic Lupus Erythematosus: Comparison of Graft Survival With Other Causes of End-stage Renal Disease. Reumatol Clínica (English Ed. 2019 May;15(3):140–5. | eng |
| dcterms.references | Soliman WM, Sherif NM, Ghanima IM, EL-Badawy MA. Neutrophil to Lymphocyte and Platelet to Lymphocyte Ratios in Systemic Lupus Erythematosus: Relation With Disease Activity and Lupus Nephritis. Reumatol Clínica (English Ed. 2020 Jul;16(4):255–61. | eng |
| dcterms.references | Miranda-Hernández D, Cruz-Reyes C, Angeles U, Jara LJ, Saavedra MA. Prognostic Factors for Treatment Response in Patients With Lupus Nephritis. Reumatol Clínica (English Ed. 2014 May;10(3):164–9. | eng |
| dcterms.references | Martín-Gómez MA, Rivera Hernández F, Frutos Sanz MÁ, Trujillo-martín MM. Recomendaciones y sugerencias a 4 preguntas clave en nefropatía lúpica: Extracto de la guía de práctica clínica 2015. Nefrología. 2016 Jul;36(4):333–8. | spa |
| dcterms.references | Llanos L, Massardo L. Tratamientos Biológicos para Nefropa- tía Lúpica. 2015;31(1):11–4. | spa |
| dcterms.references | Mofetilo M, En MFM, Lúpica N. PROTOCOLO PARA EL USO DE Código : CRFT / PRO / MNL / FIA / 122015. 2015; | spa |
| dcterms.references | Carretero M. Terapia inmunosupresora. 2014;16:140–2. | spa |
| dcterms.references | Sádaba B. Monitorización y efectos secundarios de los inmunosupresores en el tras- plante Monitoring and secondary effects of immunosuppressants in the transplant. An Sist Navar. 2006;29(2):207–18. | eng |
| dcterms.references | Carrasco-Yalán A. Anticuerpos monoclonales. Diagnóstico. 2021 Dec;60(4):204–12. | spa |
| dcterms.references | Johnson PWM, Glennie MJ. Rituximab: Mechanisms and applications. Br J Cancer. 2001;85(11):1619–23. | eng |
| oaire.version | info:eu-repo/semantics/acceptedVersion | |
| sb.programa | Especialización en Neurología | spa |
| sb.sede | Sede Barranquilla | spa |